Find Clinical Trials & Studies

Visit the Research & Education Institute

IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus PlatinumPemetrexed for EGFR-m

I'm Interested!

Please call
1-866-373-1464

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Principal Investigator
Matthew Mirsky MD

Department/Division
Cancer (Thoracic)

UH IRB: Study20251211/Pro00090675
StudyID: BRMY1525
ClinicalTrials.gov: NCT07100080

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464